Prolastin is considered relevant as a long-term support for individuals with severe, hereditary Alpha-1 Antitrypsin Deficiency (AATD). It is commonly used as a chronic augmentation and maintenance therapy for adults with clinical evidence of emphysema.

Therapeutic Role and Context

Prolastin is used as replacement therapy for people who have been diagnosed with a severe A1-PI deficiency and have clinically evident emphysema. The medication is applied across therapeutic domains where additional symptomatic support is needed due to the genetic stress that requires continuous support. It is applied in addressing the functional strain linked to the condition.

The primary indication is to provide long-term supportive relief for managing symptoms that interfere with daily functioning, including chronic shortness of breath and reduced exercise tolerance. The goal is that this support may assist in addressing the functional strain linked to organ-specific functional stress, contributing to the effort of maintaining functional stability.

“The use of this therapy may contribute to general well-being during symptomatic phases.”

Quick Facts

Property	Description
Primary Indication	Conditions presenting with severe hereditary deficiency (AATD)
Use Context	Chronic Augmentation and Maintenance Therapy
Benefit Focus	Supporting Functional Stability
Quick Fact	Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

1. NIH DailyMed Drug Information

Who Can and Cannot Use Prolastin?

The official regulatory documentation for Prolastin (Alpha-1-proteinase Inhibitor [Human]) strictly defines the eligible population and conditions for use.

Eligibility

The medicine is indicated for adults with severe hereditary Alpha-1-proteinase Inhibitor (Alpha1-PI) deficiency who also have clinical evidence of emphysema. Use is not established for patients without clinically evident emphysema or in whom severe deficiency has not been confirmed.

Contraindications (Who Must Not Use)

Prolastin is contraindicated for any patient with a known history of anaphylactic or severe systemic reactions to Alpha1-PI products. It is also prohibited for patients with selective Immunoglobulin A (IgA) deficiency who have known antibodies against IgA.

Population Restrictions

Population Group	Eligibility Status	Key Restriction/Note
Pediatric Patients	Not Established	Safety and effectiveness are not established in patients under 18 years of age.
Geriatric Patients	Insufficient Data	Clinical studies did not include sufficient subjects aged 65 and over to determine differential response.
Pregnancy/Lactation	Conditional Use	Use in pregnancy is permitted only if the potential benefit justifies the unknown risk.

The interaction profile for Prolastin, a medication containing the large, plasma-derived protein Alpha-1-proteinase Inhibitor (Human), is defined by procedural requirements and patient-specific restrictions rather than the common systemic drug-drug interactions seen with small-molecule medicines.

Mandatory Administration Restriction

A critical interaction rule governs the administration procedure. Prolastin must be infused separately and alone. Co-administration, which involves mixing the product with any other medicine or intravenous solution in the infusion line, is strictly prohibited. This restriction prevents the risk of physical or chemical incompatibility, which is a key regulatory constraint to preserve the product's integrity.

Formal Patient-Status Contraindication

A specific restriction exists based on a patient's immune status. Prolastin is formally contraindicated in individuals diagnosed with Immunoglobulin A (IgA) deficiency who also possess known antibodies against IgA (anti-IgA antibodies). This is classified as a severe interaction risk because the patient's antibodies may react with trace IgA components within the plasma-derived product, leading to the potential for severe systemic hypersensitivity.

Absence of Pharmacokinetic Interactions

Official regulatory information does not list any systemic interactions involving major metabolic pathways, such as Cytochrome P450 (CYP) enzymes, or drug transporters. There are also no documented interaction patterns with food, alcohol, or herbal products in the official labeling.

Augmentation and Mechanism of Action

Prolastin's mechanism involves replacement of the deficient Alpha-1-proteinase Inhibitor (A1-PI) protein, establishing a concentration gradient of A1-PI in the lower respiratory tract. The mechanism initiates by increasing the overall pool of functional A1-PI in the circulation, allowing it to diffuse into the pulmonary epithelial lining fluid of the lungs. This provides a source of the inhibitor, resulting in a sustained increase in the molar ratio of A1-PI to Neutrophil Elastase in the target environment.

A1-PI is a Serine Protease Inhibitor (Serpin) that acts as a suicide substrate for its primary target, Neutrophil Elastase (NE). This interaction triggers an irreversible, permanent conformational change in the A1-PI molecule, which physically traps and inactivates the NE enzyme in a stable complex. This molecular blockade impedes the proteolytic activity directed at the alveolar structures. By permanently neutralizing active NE, the mechanism halts the enzymatic cleavage of structural components in the lung, principally elastin and collagen. This inhibition maintains the structural integrity of the alveolar walls and the extracellular matrix.

Prolastin (Alpha-1-Proteinase Inhibitor [Human]) is strictly administered as a long-term augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI. The official usage guidelines outline a precise schedule and method of delivery.

Administration Protocol

The medication is to be administered exclusively by the intravenous (IV) infusion route. Prolastin is available as a lyophilized powder requiring reconstitution or as a liquid solution for injection.

Instruction	Detail
Dosing Schedule	60 mg/kg of body weight.
Frequency	Administered once weekly.
Age Group	Indicated for use only in adults.

Preparation and Delivery Constraints

For proper use, the product must be allowed to reach room temperature before preparation or administration. The prescribed dose is typically achieved by pooling the contents of multiple vials into a single sterile container.

Key procedural constraints for administration include:

• The solution must be infused separately, without mixing with other intravenous agents or diluting solutions.
• Filtration is mandatory, requiring the use of a suitable 5 to 15 micron infusion filter during administration.
• The infusion rate is controlled, usually at 0.08 mL/kg/min, resulting in an average infusion time of approximately 15 minutes for the recommended dose.
• Once prepared or pooled, the solution must be administered within a three-hour window.

These official instructions define the standardized, weight-based, once-weekly intravenous administration required for the correct long-term use of this biologic therapy.

Research Evidence / Overview of Studies for Prolastin

---

Evidence for Use in Alpha-1-Antitrypsin Deficiency (AATD) with Emphysema

Research into Prolastin, a protein replacement therapy, was studied for adults diagnosed with a severe, hereditary form of Alpha-1-antitrypsin deficiency (AATD) who also have clinical evidence of emphysema. The overall research base is comprised of different types of studies, including initial Randomized Controlled Trials (RCTs) and long-term observational registry studies.

The RCTs explored specific measurements over a few years, examining patients who received the Prolastin protein versus those who received a placebo. Large patient registries were observed in real-world settings to track the long-term patterns related to symptom development and overall health outcomes over many years. Both types of evidence contribute to the broader evidence landscape.

---

Studies Focused on Biochemical and Radiological Outcomes

Researchers primarily focused on biochemical outcomes, specifically examining whether the protein was observed to achieve and maintain levels above a threshold (e.g., >!11 mu M) in the blood. Studies reported that the administration of the medicine was associated with achieving A1-PI plasma levels above this threshold, and research describes the shift in protective activity in the blood and lung lining fluid.

Key controlled trials (RCTs lasting sim2.5 to 3 years) studies monitored the rate of change in lung density (used as a measure of emphysema progression). Findings described a difference in the rate of change in lung density between the group receiving the protein and the placebo group over the study duration.

---

Long-Term Evidence and Patient Registry Findings

To gain insight into sustained outcomes, data was evaluated in long-term observational cohort studies (registries). These studies data show patterns related to important clinical outcomes, such as overall survival.

Observational registry analyses described patterns related to survival and mortality when examining treated patients versus those who were not treated. These studies evidence suggests that receiving the Alpha-1-proteinase Inhibitor protein may be associated with patterns of survival. However, these patterns are derived from real-world, non-randomized registry data, and research provides context but not individual predictions.

---

Research Gaps and Limitations of the Evidence Base

Although different types of evidence exist, certain research limitations should be noted. The initial regulatory assessment of Prolastin was largely based on the achievement of biochemical targets and radiological surrogate endpoints. Certainty remains low for direct proof of long-term effects on traditional clinical endpoints in rigorous RCTs.

The rigorous controlled trials’ follow-up durations were limited (typically 2–3 years). Evidence quality varies across studies, with observational data offering long-term context but lacking the control of randomized trials.

Common questions about Prolastin (FAQ)

---

Q: How long does the effect of one dose of Prolastin last in the body?

A: The dosing is scheduled once a week because the Alpha-1 proteinase inhibitor has a metabolic half-life of several days. This half-life is the time it takes for half of the dose to leave the body. The weekly dose is intended to help maintain sustained protective levels of the protein in the circulation.

---

Q: Why do patients need to continue Prolastin treatment for life?

A: Prolastin is prescribed as a chronic augmentation and maintenance therapy because the underlying disease, Alpha-1-proteinase Inhibitor deficiency, is a severe hereditary disorder that lasts a lifetime. The treatment replaces the deficient protein on an ongoing basis to help maintain protective levels in the lungs.

---

Q: What signs of an allergic reaction should be watched for during or after the infusion?

A: Official safety labeling advises patients to be aware of signs of a severe allergic reaction (hypersensitivity) during or after the infusion. These signs can include hives, itching, swelling of the mouth or throat, chest tightness, or trouble breathing. If you experience any of these symptoms, contact a healthcare professional right away.

---

Q: Are there any long-term health risks associated with using Prolastin for many years?

A: Official documentation includes a Limitation of Use which notes that clinical data demonstrating the long-term effects of this chronic augmentation therapy over many years are not conclusively available from randomized, controlled clinical trials. Research continues to gather data from long-term observational patient registries to track sustained outcomes over many years.

---

Q: Are there specific medical test results that determine if Prolastin is appropriate for a patient?

A: Eligibility for treatment is determined by the diagnosis of severe hereditary deficiency of Alpha1-PI along with clinical evidence of emphysema. This diagnosis typically requires confirmation through both genetic testing (genotype) and laboratory tests showing low serum levels of the Alpha1-PI protein.

---

Q: Does Prolastin increase the risk of developing certain types of infections?

A: Since Prolastin is a product derived from human plasma (pooled blood donations), there is a theoretical risk of transmitting infectious agents, such as certain viruses. However, the manufacturing process includes rigorous steps designed to inactivate and remove these potential agents.

---

Q: Is Prolastin used to treat conditions other than Alpha-1 Antitrypsin Deficiency?

A: According to the official regulatory documents, Prolastin is only indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI. It is not indicated for treating any other medical condition.

---

Q: Has there been research on Prolastin's effectiveness in patients who are current smokers?

A: The clinical studies that support the use of Prolastin were primarily conducted in patients who were non-smokers or who had already stopped smoking. This means that data on the effectiveness of the treatment in patients who are current smokers are not included in the official documentation.

---

Q: Why are regular blood tests necessary while a person is on Prolastin?

A: Regular blood tests are necessary during treatment to monitor the Alpha-1-proteinase Inhibitor (A1-PI) protein levels in the blood. This monitoring is used to measure the A1-PI protein levels and verify they are consistently above the threshold that regulatory studies associate with anti-neutrophil elastase protection in the lungs.

---

Q: Does the manufacturing process for Prolastin minimize the risk of transmitting viruses?

A: Yes, because the product is made from pooled human plasma, the manufacturing process incorporates specific safety steps to minimize the risk of transmitting infectious agents. These steps include treatments like Solvent/Detergent treatment and Nanofiltration, which are designed to inactivate and remove potential viruses.

---

Q: What is the average duration of a Prolastin infusion appointment?

A: The actual infusion time for Prolastin, when given at the recommended rate, is typically short, averaging around 15 minutes. However, the total appointment time at a clinic or infusion center may be longer to allow for preparation, required monitoring, and observation after the infusion.

---

Q: Why is Prolastin prepared and administered by a healthcare professional instead of at home?

A: Prolastin administration typically requires a healthcare professional due to the need for complex preparation steps and the critical requirement to monitor the patient's vital signs throughout the infusion. This professional oversight is necessary to manage the risk of potential hypersensitivity reactions.

---

Q: Can Prolastin cause changes in mood or energy levels?

A: Official adverse reaction lists indicate that fatigue (a change in energy level) is a common side effect of Prolastin, reported in about 1 to 10 out of every 100 users. Information regarding other specific changes in mood is not frequently listed in the common adverse reaction tables.

---

Q: Is Prolastin considered safe for women who are breastfeeding?

A: Official product labeling indicates that there is currently no information available on the presence of Prolastin in human milk, or its effects on a breastfed infant or on milk production. Decisions regarding its use during breastfeeding require consideration of the potential benefits versus the unknown risks by a healthcare professional.

---

Q: What does the official evidence say about Prolastin slowing down lung function decline?

A: The clinical studies supporting the use of Prolastin examined the rate of change in lung density, which is a radiological measurement used to assess emphysema progression. Findings from these studies described a difference in the rate of change in lung density between the group receiving the protein and the placebo group over the study duration.

---

Q: Do studies suggest any potential benefit for non-lung-related symptoms of Alpha-1?

A: The official regulatory indication and the supporting clinical research for Prolastin are concentrated on its effect on emphysema and the pulmonary system. The product documentation does not suggest or cover potential benefits for non-lung-related symptoms of Alpha-1 antitrypsin deficiency (AATD).

How to Store and Dispose of Prolastin

Storage Conditions

Condition	Requirement
Primary Temperature	Store unopened vials refrigerated between 2 C and 8 C (36 F and 46 F).
Liquid Excursion	Prolastin-C Liquid may be kept at room temperature (up to 25 C/77 F) for a single, maximum period of one month.
Prohibited	Do not freeze the product at any time. Do not use if the solution is cloudy or discolored.

Stability and Handling

The product is dispensed in a single-use vial. Once the solution is prepared (reconstituted or pooled), it must be administered within three hours. The prepared solution cannot be refrigerated or saved. Store all medicine out of the sight and reach of children.

Disposal Instructions

All open vials, unused solution, and administration equipment must be discarded after use. Needles and other sharps must be disposed of in a designated sharps container, and all medical waste must follow local biohazard procedures.